Cagrilintide
Amylin analogue · 37-residue peptide
Identifier graph
Cross-references to canonical chemistry knowledge graphs. Each binding is the same identity used in PubMed-indexed literature.
- CAS Registry Number
- 1415456-99-3 · CAS Common Chemistry
- InChIKey
-
LDERDVMBIYGIOI-IZVMHKDJSA-N - PubChem CID
- CID 171397054
- Wikidata
- Q122341081
- ChEMBL
- CHEMBL4802169
- Molecular weight
- 4577.5 g/mol
- IUPAC name
- 20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R,3S)-1-[[(2R)-4-amino-1-[[(2R)-1-[[2-[[(2R)-1-[[(2R)-4-amino-1-[[(2R,3S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
What is Cagrilintide?
Cagrilintide (research code AM833) is a 37-residue synthetic analogue of the human pancreatic hormone amylin (islet amyloid polypeptide, IAPP), engineered for protease resistance and albumin-binding-mediated long half-life. It is developed by Novo Nordisk as a metabolic-disease candidate, and is studied in combination with Semaglutide (the CagriSema combination) in late-stage clinical programmes.
CAS 1415456-99-3, molecular weight 4577.5 g/mol. Wikidata QID Q122341081, PubChem CID 171397054, ChEMBL ID CHEMBL4802169.
Mechanism of action
Amylin is a 37-residue pancreatic peptide co-secreted with insulin from β-cells. It binds amylin receptors (heterodimers of the calcitonin receptor with receptor activity-modifying proteins, RAMP1/RAMP2/RAMP3) and produces glucagon suppression, slowed gastric emptying and central satiety signalling. Cagrilintide is engineered to be protease-resistant and to bind albumin via a C18 fatty-acid spacer, producing a plasma half-life of approximately 7 days suitable for once-weekly dosing.
Research context
The CagriSema combination (Cagrilintide + Semaglutide) is in late-stage clinical development for obesity and type-2 diabetes. Cagrilintide alone has progressed through phase II weight-management trials.
Analytical specifications
Every batch of Cagrilintide supplied by NMChem is characterised by reversed-phase HPLC for purity determination and by mass spectrometry for identity confirmation. Certificate of Analysis (COA) documents are issued per batch and made available on request.
Identity is confirmed by electrospray-ionisation mass spectrometry (ESI-MS); the observed mass falls within ±2 Da of the theoretical monoisotopic mass calculated from the residue sequence. Purity is determined by reversed-phase HPLC on a C18 column with a trifluoroacetic-acid-modified water/acetonitrile gradient and reported as the area-under-curve percentage of the main peak at 214 nm. NMChem specification is ≥99% main peak. Material ships as lyophilised powder and must be reconstituted in sterile water or bacteriostatic water immediately before use.
UK regulatory status
Supplied as a research-grade reference standard for laboratory use only. Not a licensed medicinal product in the United Kingdom and not approved by the MHRA for human or veterinary administration. Sale is restricted to researchers, institutions and laboratory professionals; the compound must be retained within research premises. End-user compliance with the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971 (where applicable) and local institutional biosafety policy is the responsibility of the buyer.
Research literature
Selected peer-reviewed publications from PubMed referencing this compound.
-
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT et al. · The New England journal of medicine · 2025
PubMed PMID 40544433 -
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Davies MJ et al. · The New England journal of medicine · 2025
PubMed PMID 40544432 -
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW et al. · Lancet (London, England) · 2021
PubMed PMID 34798060
Related compounds
Other research compounds in adjacent mechanism classes or commonly used alongside Cagrilintide.
Frequently asked questions about Cagrilintide
What is the CagriSema combination?
Get research-grade Cagrilintide from NMChem
UK supplier · HPLC and MS verified · Per-batch Certificate of Analysis · Tracked Royal Mail dispatch.